Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Michael R. Hayden net worth and biography

Michael Hayden Biography and Net Worth

Director of AbCellera Biologics

Michael is a Killam Professor of Medical Genetics at the University of British Columbia, Founder and Senior Scientist at the Centre for Molecular Medicine and Therapeutics (CMMT), and a Canada Research Chair in Human Genetics and Molecular Medicine. Michael previously served as CSO and President of Global R&D at Teva and has founded a number of biotech companies including Aspreva, Neurovir, Xenon, 89bio, and Prilenia. He has authored over 900 publications and invited submissions and is the most cited author in the world for Huntington’s Disease and ABCA1. Michael holds a number of awards including the Order of Canada (2010), the Canada Gairdner Wightman Award (2011), and the Diamond Jubilee Medal (2012). He is recognized as one of the “100 Most Inspiring People” in pharma and was inducted into the Canadian Medical Hall of Fame. He was also recently named one of the 20th century’s “50 Canadians who have changed the world”. Michael has an MB, ChB MD and a PhD degree in Genetics from the University of Cape Town.

What is Michael R. Hayden's net worth?: The estimated net worth of Michael R. Hayden is at least $228,420.16 as of March 30th, 2023. Dr. Hayden owns 83,978 shares of AbCellera Biologics stock worth more than $228,420 as of November 8th. This net worth evaluation does not reflect any other assets that Dr. Hayden may own. Learn More about Michael R. Hayden's net worth.
How do I contact Michael R. Hayden?: The corporate mailing address for Dr. Hayden and other AbCellera Biologics executives is , , . AbCellera Biologics can also be reached via phone at 604-559-9005 and via email at [email protected]. Learn More on Michael R. Hayden's contact information.
Has Michael R. Hayden been buying or selling shares of AbCellera Biologics?: Michael R. Hayden has not been actively trading shares of AbCellera Biologics during the last quarter. Most recently, Michael R. Hayden sold 100,000 shares of the business's stock in a transaction on Tuesday, June 22nd. The shares were sold at an average price of $25.50, for a transaction totalling $2,550,000.00. Learn More on Michael R. Hayden's trading history.
Who are AbCellera Biologics' active insiders?: AbCellera Biologics' insider roster includes Andrew Booth (CFO), John Hamer (Director), Carl Hansen (CEO), Michael Hayden (Director), Veronique Lecault (COO), Andrew Lo (Director), and John Montalbano (Director). Learn More on AbCellera Biologics' active insiders.

Michael R. Hayden Insider Trading History at AbCellera Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/22/2021	Sell	100,000	$25.50	$2,550,000.00

Michael R. Hayden Buying and Selling Activity at AbCellera Biologics

AbCellera Biologics Company Overview

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Today's Range

Now: $2.64

$2.63

$2.74

50 Day Range

MA: $2.63

$2.39

$2.89

2 Week Range

Now: $2.64

$2.34

$6.05

Volume

1,180,923 shs

Average Volume

1,633,271 shs

Market Capitalization

$777.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35